10x Genomics, Inc. (TXG) shareholders
Close on Nov 13, 2026Market cap $7.58BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.60%) | 18,543,562 | 15.60% | 13G (passive) amendment | Feb 27, 2026 |
| T. Rowe Price Associates, Inc. | 14,044,020 | 11.70% | 13G (passive) | Aug 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (10.80%) | 12,696,254 | 10.80% | 13G (passive) amendment | Dec 31, 2025 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (8.56%) | 10,003,058 | 8.56% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 8,496,636 | 7.60% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Portfolio Management | 6,981,683 | 5.93% | 13G (passive) | Mar 31, 2026 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (5.22%) | 6,272,998 | 5.22% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Capital Management | 6,166,597 | 5.24% | 13G (passive) | Mar 31, 2026 |
| Nikko Asset Management Americas, Inc. | 6,009,653 | 5.40% | 13G (passive) | Jun 30, 2025 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.10%), Israel A. Englander (5.10%) | 5,533,618 | 5.10% | 13G (passive) | Apr 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TXG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 17,629,266 | 13.53% | $675.91M | −111,706 | 0.03% |
| BlackRock, Inc. | 10,804,070 | 8.29% | $414.23M | +724,157 | 0.01% |
| ARK Investment Management LLC | 10,003,057 | 7.68% | $383.52M | −1,714,260 | 2.49% |
| Vanguard Portfolio Management LLC | 6,982,492 | 5.36% | $267.71M | +69,556 | 0.01% |
| Quantinno Capital Management LP | 5,469,698 | 4.20% | $209.71M | +57,937 | 0.25% |
| Vanguard Capital Management LLC | 5,082,594 | 3.90% | $194.87M | −186,992 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 4,539,007 | 3.48% | $174.03M | +4,375,792 | 0.02% |
| Sumitomo Mitsui Trust Holdings, Inc. | 4,194,627 | 3.22% | $160.82M | −915,587 | 0.09% |
| Nikko Asset Management Americas, Inc. | 4,192,517 | 3.22% | $160.74M | −911,661 | 2.07% |
| Morgan Stanley | 3,351,911 | 2.57% | $128.51M | +695,558 | 0.01% |
| Goldman Sachs Group Inc | 3,148,859 | 2.42% | $120.73M | −822,941 | 0.01% |
| Geode Capital Management, LLC | 3,082,790 | 2.37% | $118.22M | +178,562 | 0.01% |
| State Street Corp | 2,801,437 | 2.15% | $107.41M | +212,642 | 0.00% |
| Citadel Advisors LLC | 2,779,213 | 2.13% | $106.56M | +2,035,479 | 0.01% |
| Dimensional Fund Advisors LP | 2,225,284 | 1.71% | $85.31M | +182,334 | 0.02% |
| Aqr Capital Management LLC | 2,026,464 | 1.56% | $74.70M | −511,792 | 0.03% |
| Jacobs Levy Equity Management, Inc | 2,019,883 | 1.55% | $77.44M | −263,541 | 0.28% |
| Point72 Asset Management, L.P. | 1,852,776 | 1.42% | $71.04M | New | 0.08% |
| Capital World Investors | 1,493,031 | 1.15% | $57.24M | +40,731 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 1,266,954 | 0.97% | $48.58M | −12,428 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 391 | 129M | 98.7% | 100 / 99 | 140 / 33 | 20M | 16M |
| Q1 2026 | 331 | 125M | 96.1% | 57 / 115 | 103 / 42 | 30M | 16M |
| Q4 2025 | 322 | 124M | 95.3% | 64 / 108 | 98 / 58 | 18M | 18M |
| Q3 2025 | 318 | 124M | 95.2% | 67 / 99 | 90 / 42 | 22M | 21M |
| Q2 2025 | 297 | 123M | 94.3% | 74 / 112 | 74 / 50 | 32M | 23M |
| Q1 2025 | 274 | 114M | 87.7% | 48 / 109 | 75 / 45 | 26M | 16M |
| Q4 2024 | 273 | 105M | 80.4% | 62 / 89 | 92 / 49 | 18M | 16M |
| Q3 2024 | 266 | 105M | 80.4% | 58 / 103 | 73 / 49 | 22M | 16M |
| Q2 2024 | 261 | 105M | 81.0% | 36 / 112 | 78 / 62 | 20M | 27M |
| Q1 2024 | 290 | 114M | 87.4% | 60 / 114 | 76 / 42 | 24M | 12M |
| Q4 2023 | 275 | 102M | 78.3% | 61 / 98 | 80 / 37 | 17M | 5M |
| Q3 2023 | 256 | 91M | 70.1% | 33 / 81 | 101 / 49 | 10M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
299 funds held TXG in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TXG | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 3,887,549 | 2.98% | $183.76M | 3.30% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 3,528,683 | 2.71% | $135.29M | 0.01% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 3,094,931 | 2.38% | $146.30M | 9.39% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 3,031,869 | 2.33% | $116.24M | 0.14% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,548,523 | 1.96% | $97.71M | 0.05% | Jun 30, 2026 |
| Select Medical Technology and Devices Portfolio | 2,065,224 | 1.59% | $58.46M | 1.96% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,735,975 | 1.33% | $49.14M | 0.02% | May 31, 2026 |
| Select Health Care Portfolio | 1,600,000 | 1.23% | $45.29M | 0.78% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,467,202 | 1.13% | $56.25M | 0.12% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,458,300 | 1.12% | $55.91M | 0.38% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,452,300 | 1.11% | $55.68M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,341,063 | 1.03% | $51.42M | 0.05% | Jun 30, 2026 |
| VIP Mid Cap Portfolio | 1,321,800 | 1.01% | $50.68M | 0.53% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,321,693 | 1.01% | $50.67M | 0.52% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,303,727 | 1.00% | $61.63M | 0.18% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Serge Saxonov | Chief Executive Officer, Director | 4,122,758 | 3.16% | Nov 13, 2026 |
| Benjamin J. Hindson | See Remarks, Director | 488,182 | 0.37% | Aug 26, 2026 |
| Adam Taich | Chief Financial Officer | 330,098 | 0.25% | Sep 11, 2026 |
| Ansuman Satpathy | Director | – | – | Nov 6, 2026 |
| Joseph E. Gilliam | Director | 31 | 0.00% | Nov 6, 2026 |
| Shehnaaz Suliman | Director | 23,792 | 0.02% | Sep 24, 2026 |
| John R. Stuelpnagel | Director | 328,436 | 0.25% | Sep 8, 2026 |
| Sarah A. Teichmann | Director | 28,058 | 0.02% | Aug 17, 2026 |
| Kimberly J. Popovits | Director | 37,445 | 0.03% | Jun 8, 2026 |
| Alan Mateo | Director | 85,877 | 0.07% | Jun 8, 2026 |
| Sridhar Kosaraju | Director | 68,278 | 0.05% | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Serge Saxonov Chief Executive Officer, Director | Nov 10, 2026 | Sale | −31,000 | $62.90 | $1.95M | 1,019,249 |
| Shehnaaz Suliman Director | Sep 22, 2026 | Sale(10b5-1 plan) | −1,222 | $82.28 | $100.55K | 23,792 |
| Shehnaaz Suliman Director | Sep 22, 2026 | Sale(10b5-1 plan) | −614 | $79.51 | $48.82K | 28,609 |
| Shehnaaz Suliman Director | Sep 22, 2026 | Sale(10b5-1 plan) | −292 | $78.20 | $22.83K | 29,223 |
| Shehnaaz Suliman Director | Sep 22, 2026 | Sale(10b5-1 plan) | −2,270 | $81.67 | $185.39K | 25,014 |
| Shehnaaz Suliman Director | Sep 22, 2026 | Sale(10b5-1 plan) | −1,325 | $80.82 | $107.09K | 27,284 |
| Serge Saxonov Chief Executive Officer, Director | Sep 22, 2026 | Sale(10b5-1 plan) | −2,800 | $82.37 | $230.64K | 1,050,249 |
| Serge Saxonov Chief Executive Officer, Director | Sep 22, 2026 | Sale(10b5-1 plan) | −2,000 | $79.62 | $159.24K | 1,072,249 |
| Serge Saxonov Chief Executive Officer, Director | Sep 22, 2026 | Sale(10b5-1 plan) | −9,300 | $80.90 | $752.37K | 1,062,949 |
| Serge Saxonov Chief Executive Officer, Director | Sep 22, 2026 | Sale(10b5-1 plan) | −9,900 | $81.83 | $810.12K | 1,053,049 |
| Serge Saxonov Chief Executive Officer, Director | Sep 22, 2026 | Sale(10b5-1 plan) | −1,000 | $78.23 | $78.23K | 1,074,249 |
| Adam Taich Chief Financial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −31,428 | $64.31 | $2.02M | 330,098 |
| Adam Taich Chief Financial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −13,754 | $65.26 | $897.59K | 316,344 |
| Adam Taich Chief Financial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −1,206 | $63.68 | $76.80K | 361,526 |
| John R. Stuelpnagel Director | Sep 3, 2026 | Sale | −6,174 | $62.61 | $386.55K | 328,436 |
| John R. Stuelpnagel Director | Sep 3, 2026 | Sale | −7,012 | $60.66 | $425.35K | 341,424 |
| John R. Stuelpnagel Director | Sep 3, 2026 | Sale | −6,814 | $62.11 | $423.22K | 334,610 |
| Serge Saxonov Chief Executive Officer, Director | Sep 1, 2026 | Gift | −100 | – | – | 1,075,249 |
| Serge Saxonov Chief Executive Officer, Director | Aug 26, 2026 | Sale(10b5-1 plan) | −492 | $64.75 | $31.86K | 1,075,349 |
| Serge Saxonov Chief Executive Officer, Director | Aug 26, 2026 | Sale(10b5-1 plan) | −6,494 | $63.98 | $415.49K | 1,075,841 |
| Serge Saxonov Chief Executive Officer, Director | Aug 26, 2026 | Sale(10b5-1 plan) | −3,500 | $63.02 | $220.57K | 1,082,335 |
| Adam Taich Chief Financial Officer | Aug 24, 2026 | Sale | −17,166 | $63.02 | $1.08M | 362,732 |
| Serge Saxonov Chief Executive Officer, Director | Aug 24, 2026 | Sale | −18,545 | $63.02 | $1.17M | 1,085,835 |
| Benjamin J. Hindson See Remarks, Director | Aug 24, 2026 | Sale | −13,818 | $63.02 | $870.81K | 488,182 |
| Shehnaaz Suliman Director | Aug 24, 2026 | Sale(10b5-1 plan) | −1,646 | $63.97 | $105.29K | 29,515 |
| Shehnaaz Suliman Director | Aug 24, 2026 | Sale(10b5-1 plan) | −561 | $62.73 | $35.19K | 31,161 |
| Serge Saxonov Chief Executive Officer, Director | Aug 20, 2026 | Gift | −4,000 | – | – | 1,104,380 |
| Sarah A. Teichmann Director | Aug 14, 2026 | Sale(10b5-1 plan) | −2,273 | $57.15 | $129.90K | 28,058 |
| Sarah A. Teichmann Director | Aug 13, 2026 | Sale(10b5-1 plan) | −5,278 | $57.29 | $302.38K | 30,331 |
| John R. Stuelpnagel Director | Aug 11, 2026 | Sale | −17,000 | $57.58 | $978.86K | 351,436 |
| John R. Stuelpnagel Director | Aug 11, 2026 | Sale | −3,000 | $58.73 | $176.19K | 348,436 |
| Serge Saxonov Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −9,991 | $34.28 | $342.49K | 1,119,862 |
| Serge Saxonov Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −9,821 | $35.32 | $346.88K | 1,110,041 |
| Serge Saxonov Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −1,661 | $36.16 | $60.06K | 1,108,380 |
| Serge Saxonov Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −8,527 | $33.29 | $283.86K | 1,129,853 |
| Shehnaaz Suliman Director | Jun 16, 2026 | Sale(10b5-1 plan) | −364 | $33.27 | $12.11K | 31,722 |
| Shehnaaz Suliman Director | Jun 16, 2026 | Sale(10b5-1 plan) | −5,359 | $32.59 | $174.65K | 32,086 |
| Shehnaaz Suliman Director | Jun 4, 2026 | Award | +8,829 | – | – | 37,445 |
| John R. Stuelpnagel Director | Jun 4, 2026 | Award | +8,829 | – | – | 368,436 |
| Sarah A. Teichmann Director | Jun 4, 2026 | Award | +8,829 | – | – | 35,609 |
| Kimberly J. Popovits Director | Jun 4, 2026 | Award | +8,829 | – | – | 37,445 |
| Sridhar Kosaraju Director | Jun 4, 2026 | Award | +8,829 | – | – | 65,278 |
| Alan Mateo Director | Jun 4, 2026 | Award | +8,829 | – | – | 85,877 |
| Serge Saxonov Chief Executive Officer, Director | May 26, 2026 | Sale(10b5-1 plan) | −10,718 | $24.71 | $264.84K | 1,138,380 |
| Benjamin J. Hindson See Remarks, Director | May 22, 2026 | Sale | −11,595 | $24.44 | $283.38K | 502,000 |
| Serge Saxonov Chief Executive Officer, Director | May 22, 2026 | Sale(10b5-1 plan) | −18,175 | $24.44 | $444.20K | 1,149,098 |
| Adam Taich Chief Financial Officer | May 22, 2026 | Sale | −15,098 | $24.44 | $369.00K | 379,898 |
| Serge Saxonov Chief Executive Officer, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −5,000 | $24.56 | $122.80K | 1,167,273 |
| Serge Saxonov Chief Executive Officer, Director | Mar 24, 2026 | Sale(10b5-1 plan) | −5,000 | $19.52 | $97.60K | 1,172,273 |
| Serge Saxonov Chief Executive Officer, Director | Mar 23, 2026 | Sale(10b5-1 plan) | −10,000 | $19.13 | $191.30K | 1,177,273 |
| Serge Saxonov Chief Executive Officer, Director | Mar 3, 2026 | Gift | −2,750 | – | – | 1,200,917 |
| Serge Saxonov Chief Executive Officer, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −1,860 | $23.18 | $43.11K | 1,203,667 |
| Serge Saxonov Chief Executive Officer, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −14,292 | $22.67 | $324.00K | 1,205,527 |
| Serge Saxonov Chief Executive Officer, Director | Feb 26, 2026 | Award | +157,895 | – | – | 1,219,819 |
| Benjamin J. Hindson See Remarks, Director | Feb 26, 2026 | Award | +88,816 | – | – | 513,595 |
| Adam Taich Chief Financial Officer | Feb 26, 2026 | Award | +106,579 | – | – | 394,996 |
| Sarah A. Teichmann Director | Feb 25, 2026 | Sale(10b5-1 plan) | −7,579 | $19.41 | $147.11K | 26,780 |
| Serge Saxonov Chief Executive Officer, Director | Feb 23, 2026 | Sale | −9,632 | $18.58 | $178.96K | 1,061,924 |
| Benjamin J. Hindson See Remarks, Director | Feb 23, 2026 | Sale | −7,826 | $18.58 | $145.41K | 424,779 |
| Adam Taich Chief Financial Officer | Feb 23, 2026 | Sale | −8,968 | $18.58 | $166.63K | 288,417 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of 10x Genomics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 104,581 shares on Sep 11, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shehnaaz Suliman Affiliate | Sep 22, 2026 | 5,723 | $452.69K | Sep 22, 2026 | RSU Vesting |
| Adam Taich Officer | Sep 9, 2026 | 46,388 | $3.00M | Sep 9, 2026 | Restricted Stock |
| John R. Stuelpnagel Director | Sep 3, 2026 | 20,000 | $1.24M | Sep 3, 2026 | Granted as founders shares |
| Serge Saxonov Director, CEO | Aug 26, 2026 | 35,486 | $2.21M | Aug 26, 2026 | RSU Vesting |
| Shehnaaz Suliman Affiliate | Aug 24, 2026 | 2,207 | $143.72K | Aug 24, 2026 | RSU Vesting |
| Serge Saxonov Officer, Director | Aug 24, 2026 | 17,948 | $1.17M | Aug 24, 2026 | Restricted Stock Unit Grant |
| Benjamin J. Hindson Officer, Director | Aug 24, 2026 | 13,373 | $870.85K | Aug 24, 2026 | Restricted Stock Unit Grant |
| Adam Taich Officer | Aug 24, 2026 | 16,614 | $1.08M | Aug 24, 2026 | Restricted Stock Unit Grant |
| Sarah A. Teichmann Director | Aug 14, 2026 | 2,273 | $129.90K | Aug 14, 2026 | Restricted Stock |
| Sarah A. Teichmann Director | Aug 13, 2026 | 5,278 | $302.38K | Aug 13, 2026 | Restricted Stock |
| John R. Stuelpnagel Director | Aug 11, 2026 | 20,000 | $1.16M | Aug 11, 2026 | Granted as founders shares |
| Shehnaaz Suliman Affiliate | Jun 16, 2026 | 5,723 | $184.40K | Jun 16, 2026 | RSU Vesting |
| Serge Saxonov Director, CEO | May 26, 2026 | 40,718 | $964.20K | May 26, 2026 | RSU Vesting |
| Adam Taich Officer | May 22, 2026 | 11,779 | $290.71K | May 22, 2026 | Restricted Stock Unit Grant |
| Benjamin J. Hindson Officer, Director | May 22, 2026 | 9,430 | $232.73K | May 22, 2026 | Restricted Stock Unit Grant |
See a number that looks wrong?